RA

Walgreens, AllianceRx Walgreens Pharmacy Study of Non-Infused Biologics in Rheumatoid Arthritis Treatment Underscores Importance of Medication Adherence

Retrieved on: 
Wednesday, September 20, 2023

ORLANDO, Fla., Sept. 20, 2023 /PRNewswire/ -- A recent study evaluating the use of non-infused biologics in patients diagnosed with rheumatoid arthritis (RA) demonstrated that patients who are adherent to their non-infused RA biologic medication are more likely to have lower medical costs, odds of hospitalization and length of stay (LOS). AllianceRx Walgreens Pharmacy, a leading specialty and home delivery pharmacy, and Walgreens, one of the largest drug store chains in the U.S., conducted the retrospective cohort study.

Key Points: 
  • AllianceRx Walgreens Pharmacy , a leading specialty and home delivery pharmacy, and Walgreens , one of the largest drug store chains in the U.S., conducted the retrospective cohort study .
  • The Pharmacy Quality Alliance (PQA) promotes a useful reporting metric of proportion of days covered (PDC) for non-infused biologic medications to treat RA.
  • Renee Baiano, PharmD, CSP , clinical program manager for AllianceRx Walgreens Pharmacy and an author of the study, says the research findings underscore the importance of patients remaining adherent to their therapy.
  • "Identifying barriers to adherence and educating patients on the importance of taking their medication can increase the patient's chance at disease improvement," says Dr. Baiano.

Nostromo Energy's IceBrick® Energy Storage Systems Awarded First Resource Adequacy Credits by the California Public Utilities Commission

Retrieved on: 
Tuesday, September 19, 2023

IRVINE, Calif., Sept. 19, 2023 /PRNewswire/ -- Nostromo Energy, Inc. (TASE: NOST), provider of the IceBrick® system, a virtual power plant (VPP)-enabled distributed thermal energy storage solution for commercial and industrial (C&I) buildings, announced today that the California Public Utilities Commission (CPUC) awarded Nostromo's IceBrick energy storage systems Resource Adequacy (RA) eligible Qualified Capacity for 2024 as Demand Response (DR) resources.

Key Points: 
  • Utilities and community choice aggregators (CCAs) in California must procure qualified capacity to meet their resources adequacy obligations, set by the CPUC, but resources are slow to come online due to long interconnection queues, which average above 4 years in California.
  • The IceBrick systems, as dispatchable, supply-side, behind-the-meter thermal energy storage technology, are not subject to these queues and can be online within 6-9 months from contracting with the site owner.
  • "We look forward to partnering with utilities and CCAs on deploying IceBrick systems in their service area to provide local RA while helping their customers reduce their energy costs and carbon emissions."
  • The systems will operate as an automated VPP via remote management and are capable of dispatching energy to lower demands according to grid signals.

LS Energy Solutions and Gore Street Energy Storage Fund Partner on 200 MW/400 MWh Energy Storage Project

Retrieved on: 
Thursday, September 7, 2023

CHARLOTTE, N.C., Sept. 07, 2023 (GLOBE NEWSWIRE) -- LS Energy Solutions (“LS-ES”) , a leading provider of grid-connected energy storage solutions, announced today that the company is deploying 200 MW/400 MWh of energy storage to a site in Southern California.

Key Points: 
  • CHARLOTTE, N.C., Sept. 07, 2023 (GLOBE NEWSWIRE) -- LS Energy Solutions (“LS-ES”) , a leading provider of grid-connected energy storage solutions, announced today that the company is deploying 200 MW/400 MWh of energy storage to a site in Southern California.
  • Gore Street Energy Storage Fund (LON: GSF) is developing the Imperial County project, named Big Rock, which will use 137 AiON-ESS units in the largest LS-ES installation yet.
  • “The Big Rock energy storage system is a major step forward for Gore Street Energy Storage Fund and for LS Energy Solutions.
  • Big Rock joins other energy storage investments by the Gore Street Energy Storage Fund in Texas, Ireland, Great Britain, and Germany.

Shields Health Solutions Consistently Demonstrates Superior Clinical Outcomes

Retrieved on: 
Tuesday, September 12, 2023

Shields Health Solutions (Shields), the premier specialty pharmacy accelerator in the country, recently published its latest patient outcomes in key disease states such as hepatitis C, HIV, rheumatoid arthritis (RA), and multiple sclerosis (MS).

Key Points: 
  • Shields Health Solutions (Shields), the premier specialty pharmacy accelerator in the country, recently published its latest patient outcomes in key disease states such as hepatitis C, HIV, rheumatoid arthritis (RA), and multiple sclerosis (MS).
  • Through collaboration with its health system partners nationwide, these industry-leading patient outcomes further illustrate the effectiveness of Shields’ integrated care model.
  • “We are thrilled to reinforce our reputation as the nation’s leading specialty pharmacy partner through our exceptional outcomes in various complex disease states,” said Brian S. Smith, PharmD, Chief Pharmacy Officer at Shields.
  • Furthermore, 93% of Shields patients reported their condition improved or stabilized since receiving care through the network of integrated health system specialty pharmacies.

Celltrion Celebrates a Decade of Biosimilar Innovation in Europe

Retrieved on: 
Sunday, September 10, 2023

Celltrion Healthcare today launches a campaign to celebrate a decade of continuous biosimilar innovation in Europe.

Key Points: 
  • Celltrion Healthcare today launches a campaign to celebrate a decade of continuous biosimilar innovation in Europe.
  • The campaign coincides with 10 years since the world’s first monoclonal antibody biosimilar infliximab, Remsima®, received regulatory approval from the European Medicines Agency (EMA).
  • This sustained innovation and evolution of biosimilars has delivered benefits beyond their reference product.
  • Biosimilars made it possible to reduce treatment prices - it was an economic revolution for patients and healthcare systems.”
    In celebration of a decade of innovation and commitment to IMID treatment landscape, Celltrion is launching an innovative campaign across Europe.

Mariana Oncology Announces $175 Million Series B Financing

Retrieved on: 
Thursday, September 7, 2023

Mariana Oncology Inc., a biotechnology company pioneering a new era of radiopharmaceutical innovation to treat cancers with high unmet need, today announced the closing of an oversubscribed $175 million Series B financing co-led by Deep Track Capital and Forbion.

Key Points: 
  • Mariana Oncology Inc., a biotechnology company pioneering a new era of radiopharmaceutical innovation to treat cancers with high unmet need, today announced the closing of an oversubscribed $175 million Series B financing co-led by Deep Track Capital and Forbion.
  • Proceeds from the financing will support the advancement of Mariana Oncology’s novel portfolio of precision, next-generation radiopharmaceuticals including its lead candidate, MC-339, as the company transitions into a clinical-stage organization.
  • "The support of such a strong syndicate of new and existing investors is a testament to Mariana Oncology’s potential,” said Simon Read, Ph.D., Founder and Chief Executive Officer of Mariana Oncology.
  • “In just 18 months since our Series A, we’ve leveraged our deep expertise in peptide discovery and radiochemistry to advance a diversified portfolio of novel molecules.

Scipher Medicine Receives Medicare Coverage for PrismRA® Test in Rheumatoid Arthritis Patients

Retrieved on: 
Thursday, September 7, 2023

Scipher Medicine Corporation, a precision immunology company matching each patient with their most effective therapy, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC), and Centers for Medicare and Medicaid Services (CMS) published a local coverage determination (LCD) for molecular biomarker testing to guide targeted therapy selection in rheumatoid arthritis (RA) patients.

Key Points: 
  • Scipher Medicine Corporation, a precision immunology company matching each patient with their most effective therapy, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC), and Centers for Medicare and Medicaid Services (CMS) published a local coverage determination (LCD) for molecular biomarker testing to guide targeted therapy selection in rheumatoid arthritis (RA) patients.
  • The coverage decision includes PrismRA, Scipher’s innovative molecular diagnostic test that guides treatment selection for patients with RA.
  • “Precision medicine will now be accessible to many patients suffering from rheumatoid arthritis, a potentially debilitating disease if not treated with the right therapy,” Scipher Medicine CEO Alif Saleh said.
  • “This coverage decision not only represents a significant benefit for patients today but also ushers in a new era of precision medicine in autoimmune diseases.”
    Access to PrismRA will benefit eligible patients within Medicare who covers approximately 66 million lives in the United States.

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

Retrieved on: 
Wednesday, September 13, 2023

Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.

Key Points: 
  • Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.
  • Subject to the terms of the agreement, Astellas will receive total payments of up to €5.5 million including upfront and milestone payments.
  • In addition, Menarini will pay Astellas a high-single digit percentage royalties on net sales of Smyraf®.
  • Menarini will have an option to extend the rights to select South-East Asian markets.

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

Retrieved on: 
Wednesday, September 13, 2023

Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.

Key Points: 
  • Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.
  • Subject to the terms of the agreement, Astellas will receive total payments of up to €5.5 million including upfront and milestone payments.
  • In addition, Menarini will pay Astellas a high-single digit percentage royalties on net sales of Smyraf®.
  • Menarini will have an option to extend the rights to select South-East Asian markets.

Biogen Appoints Jane Grogan as Head of Research

Retrieved on: 
Wednesday, September 6, 2023

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023.
  • Dr. Grogan will be a member of Biogen’s Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer.
  • Grogan is a pioneering scientist whose groundbreaking discoveries at Genentech helped pave the way for development of targeted autoimmune and oncology therapies.
  • At Genentech, Dr. Grogan also integrated strategy between Early Discovery Research, Clinical Development, and Business Development and was project leader for engineered T cell therapies.